United States Eventing Association

The United States Eventing Association (USEA) is excited and honored to welcome back longtime sponsor Adequan® i.m. (polysulfated glycosaminoglycan) as the “Official Joint Therapy Treatment of the USEA” and the Title Sponsor of the popular Adequan® USEA Gold Cup Series.

Allyn Mann, Director of the Animal Health Division at Luitpold, offered his thoughts on The Adequan® Gold Cup Series. “We are very honored to be able to support the Eventing community through this competition. These elite riders and their amazing horses make the sport one of the most exciting to watch from a spectators view. The winner’s payout of $20,000 is second only to the Rolex [Kentucky] Three-Day Event payout for U.S. riders. Wishing all owners and riders a successful 2015 season.”

Now in its twelfth year, the Adequan® USEA Gold Cup Series encompasses eleven of the top eventing competitions around the United States at the Advanced and CIC3* levels. The Series will culminate with the Adequan® USEA Gold Cup Final held in Tyler, Texas at the 2015 Nutrena USEA American Eventing Championships in September.

Due to the outstanding support from Adequan® i.m., there is a lot at stake for Gold Cup Series competitors. The Adequan® USEA Gold Cup Champion receives one of the highest payouts in the sport of Eventing in the United States, second only to the prestigious Rolex Kentucky Three-Day Event. Walking away with a $20,000 check, the Adequan® USEA Gold Cup Champion is a highly-coveted title among top event riders around the country.

“The commitment of Adequan® i.m. and its parent company Luitpold to the health and welfare of equine athletes, event horses and the viability of equestrian sport has once again been proven through their sponsorship of U.S. Eventing,” stated USEA COO Rob Burk. “We are lucky to have an amazing product in Adequan® i.m. for the well-being of our horses, and to have an amazing partner that reinvests in our sport.”

The winners of the 11 Adequan® USEA Gold Cup Series qualifying events take home at least $500 in prize money and a 7-dose box of Adequan® i.m., along with prizes from many other supporting sponsors.

Adequan® i.m. is an integral part of the USEA family of sponsors, and the USEA is overjoyed to have them back on board for another three years.

About the USEA

The USEA is a non-profit 501 C (3), educational organization committed to providing eventing enthusiasts with a competitive level suited to their individual skills. By assisting and educating competitors, event organizers and officials; maintaining responsible safety standards; and registering qualified competitions and clinics, the USEA offers a strong and continuous training opportunity for an ever-expanding field of world-class competitors. Just as importantly, the USEA provides a means for all riders, regardless of age or ability, to experience the thrill of eventing.

About Adequan® i.m. (polysulfated glycosaminoglycan)

Maintaining the health and soundness of equine athletes is one of the keys to their success. Adequan® i.m. is a veterinarian-trusted name in the fight against equine degenerative joint disease. Luitpold Animal Health is committed to advancing the cause of better animal health through scientifically proven and FDA-approved products. Adequan® i.m. is the only FDA-approved intramuscular polysulfated glycosaminoglycan for equine. Early treatment with Adequan® i.m. can stop the destructive disease cycle, reverse degenerative joint disease and improve joint function. If your equine athlete or companion horse is experiencing degenerative joint disease, speak to your veterinarian and find out if Adequan® i.m., “The Winning Formula for Champions,” can benefit your horse.

Adequan® i.m. Brief Summary

Brief Summary Indications: For the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. There are no known contraindications to the use of intramuscular Adequan® i.m. brand Polysulfated Glycosaminoglycan in horses. Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Each 5 mL contains 500 mg Polysulfated Glycosaminoglycan. SEE PRODUCT PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION at www.adequan.com

Adequan® is a registered trademark of Luitpold Pharmaceuticals, Inc. ©LUITPOLD PHARMACEUTICALS, INC., Animal Health Division, Shirley, NY 11967.

SEE PRODUCT PACKAGE INSERTS AT WWW.ADEQUAN.COM FOR FULL PRESCRIBING INFORMATION